Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Malar J ; 11: 152, 2012 May 03.
Article in English | MEDLINE | ID: mdl-22554149

ABSTRACT

BACKGROUND: Although early diagnosis and prompt treatment is an important strategy for control of malaria, using fever to initiate presumptive treatment with expensive artemisinin combination therapy is a major challenge; particularly in areas with declining burden of malaria. This study was conducted using community-owned resource persons (CORPs) to provide early diagnosis and treatment of malaria, and collect data for estimation of malaria burden in four villages of Korogwe district, north-eastern Tanzania. METHODS: In 2006, individuals with history of fever within 24 hours or fever (axillary temperature ≥37.5°C) at presentation were presumptively treated using sulphadoxine/pyrimethamine. Between 2007 and 2010, individuals aged five years and above, with positive rapid diagnostic tests (RDTs) were treated with artemether/lumefantrine (AL) while under-fives were treated irrespective of RDT results. Reduction in anti-malarial consumption was determined by comparing the number of cases that would have been presumptively treated and those that were actually treated based on RDTs results. Trends of malaria incidence and slide positivity rates were compared between lowlands and highlands. RESULTS: Of 15,729 cases attended, slide positivity rate was 20.4% and declined by >72.0% from 2008, reaching <10.0% from 2009 onwards; and the slide positivity rates were similar in lowlands and highlands from 2009 onwards. Cases with fever at presentation declined slightly, but remained at >40.0% in under-fives and >20.0% among individuals aged five years and above. With use of RDTs, cases treated with AL decreased from <58.0% in 2007 to <11.0% in 2010 and the numbers of adult courses saved were 3,284 and 1,591 in lowlands and highlands respectively. Malaria incidence declined consistently from 2008 onwards; and the highest incidence of malaria shifted from children aged <10 years to individuals aged 10-19 years from 2009. CONCLUSIONS: With basic training, supervision and RDTs, CORPs successfully provided early diagnosis and treatment and reduced consumption of anti-malarials. Progressively declining malaria incidence and slide positivity rates suggest that all fever cases should be tested with RDTs before treatment. Data collected by CORPs was used to plan phase 1b MSP3 malaria vaccine trial and will be used for monitoring and evaluation of different health interventions. The current situation indicates that there is a remarkable changing pattern of malaria and these areas might be moving from control to pre-elimination levels.


Subject(s)
Antimalarials/administration & dosage , Artemisinins/administration & dosage , Community Health Workers , Ethanolamines/administration & dosage , Fluorenes/administration & dosage , Malaria/diagnosis , Malaria/drug therapy , Adolescent , Adult , Artemether, Lumefantrine Drug Combination , Blood/parasitology , Child , Child, Preschool , Drug Combinations , Early Diagnosis , Health Services Research , Humans , Incidence , Infant , Infant, Newborn , Malaria/epidemiology , Parasitemia/diagnosis , Pyrimethamine/administration & dosage , Sulfadoxine/administration & dosage , Tanzania/epidemiology , Young Adult
2.
Ann R Coll Surg Engl ; 92(5): W45-6, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20529483

ABSTRACT

A 38-year-old Afro-Caribbean woman, who was pre-dialysis with polycystic kidney disease, received a live-donor kidney transplant from her 55-year-old mother. This study documents her imunosuppression therapy including resolution of an oral Kaposi's sarcoma and explores the many underlying problems with converting to an mTOR inhibitor.


Subject(s)
Immunosuppressive Agents/adverse effects , Kidney Transplantation/immunology , Mouth Neoplasms/immunology , Sarcoma, Kaposi/immunology , Adult , Female , Graft Rejection/prevention & control , Humans , Immunocompromised Host , Immunosuppressive Agents/therapeutic use , Polycystic Kidney Diseases/surgery , Sirolimus/therapeutic use
4.
Br J Surg ; 96(6): 685-91, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19434702

ABSTRACT

BACKGROUND: Function and survival of non-heart-beating donor (NHBD) renal transplants have been shown to be comparable to those from heart-beating donors (HBDs) up to 10 years after transplantation. However, there are few data on outcome after 10 years, particularly from uncontrolled NHBD donors. METHODS: All NHBD renal transplants (predominantly uncontrolled) performed between April 1992 and January 2002 were retrospectively matched with HBD renal transplants performed over the same period. RESULTS: Some 112 NHBD renal transplants were compared with 164 HBD renal transplants. Delayed graft function was significantly higher in the NHBD group (83.9 versus 22.0 per cent respectively; P < 0.001). Primary non-function rates were similar (5.4 versus 1.8 per cent respectively; P = 0.164). Overall serum creatinine was significantly higher in NHBDs (P < 0.001). Median graft and patient survival was 126 months for NHBD and 159 months for HBD kidneys. Death-censored graft survival at 1, 5, 10 and 15 years was respectively 91.8, 77.5, 61.0 and 44.2 per cent for NHBD, and 91.1, 86.3, 71.7 and 58.5 per cent for HBD kidneys (P = 0.108). CONCLUSION: Despite increased delayed graft function rates and serum creatinine levels, the long-term survival of NHBD renal transplants was similar to those from HBDs. However, there was a trend to poorer function and survival from 10 years after transplant.


Subject(s)
Delayed Graft Function/etiology , Kidney Transplantation/methods , Living Donors , Analysis of Variance , Cadaver , Case-Control Studies , Delayed Graft Function/mortality , Female , Graft Rejection , Graft Survival , Humans , Kidney Transplantation/mortality , Male , Middle Aged , Survival Analysis , Time Factors , Treatment Outcome
5.
Ann R Coll Surg Engl ; 89(5): 504-9, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17688724

ABSTRACT

INTRODUCTION: The incidence of fragility fractures could double in the next 50 years. Effective treatments for osteoporosis exist and the British Orthopaedic Association (BOA) has guidelines governing how to manage underlying osteoporosis in patients with fragility fractures. This study assessed how well two trauma units treat underlying osteoporosis and whether the BOA guidelines made any impact. PATIENTS AND METHODS: Case notes of patients with a fracture of their proximal femur admitted during January and February in 2003, 2004 and 2005 were reviewed. The results were analysed for differences between site and year. RESULTS: A total of 602 case notes were reviewed. There was a significant difference in the number of patients discharged on osteoporosis medication between the two sites (27% at LRI, 8% at KGH; P < 0.001), but not between 2003 and 2005 (22% and 16%; P = 0.16). Of the patients started on treatment, 83% were started on calcium and/or vitamin D(3) supplements. CONCLUSIONS: The number of patients who had their underlying osteoporosis addressed was low and the type of treatment sub-optimal. This suggests the BOA guidelines have not made an impact and further work is required to improve the management of these patients.


Subject(s)
Femoral Fractures/surgery , Fractures, Spontaneous/surgery , Osteoporosis/complications , Aged , Aged, 80 and over , Bone Density Conservation Agents/therapeutic use , Diphosphonates/therapeutic use , Fractures, Spontaneous/etiology , Humans , Length of Stay , Middle Aged , Postoperative Care/statistics & numerical data , Practice Guidelines as Topic , Preoperative Care/statistics & numerical data , Professional Practice , Risk Factors , Waiting Lists
SELECTION OF CITATIONS
SEARCH DETAIL
...